CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer

Journal of Clinical Psychopharmacology

Volumn 31, Issue 4, 2011, Pages 463-469

  Wang, Sheng Chang ^a,b   Ho, Ing Kang ^a   Tsou, Hsiao Hui ^a   Tian, Jia Ni ^a   Hsiao, Chin Fu ^a   Chen, Chia Hui ^a   Tan, Happy Kuy Lok ^b   Lin, Linen ^c   Wu, Chi Shin ^d   Su, Lien Wen ^e   Huang, Chieh Liang ^f,g   Yang, Yi Hong ^e   Liu, Ming Lun ^h   Lin, Keh Ming ^a   Chen, Chun Yu ^a   Liu, Shu Chih ^a   Wu, Hsiao Yu ^a   Chan, Hsiu Wen ^a   Tsai, Ming Hsien ⁱ   Lin, Pei Sheng ^a   Liu, Yu Li ^a   more..

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b Taoyuan Mental Hospital   (Taiwan)

^c EN CHU KONG HOSPITAL   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

^h Wei Gong Memorial Hospital   (Taiwan)

ⁱ KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

CYP2B6; heroin addiction; methadone; S enantiomer; SNP

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; CYTOCHROME P450 2B6; METHADONE; NUCLEOTIDE;

ADULT; ALLELE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG CLEARANCE; ENANTIOMER; ENZYME POLYMORPHISM; EXON; FEMALE; HAPLOTYPE; HUMAN; HUMAN CELL; INTRON; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; FEMALE; HAPLOTYPES; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHADONE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, SINGLE NUCLEOTIDE; STEREOISOMERISM;

EID: 79960598589     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318222b5dd     Document Type: Article

References (35)

1. World Health Organization. WHO Model Lists of Essential Medicines. 16th ed. Geneva, Switzerland: World Health Organization; 2009.
2. Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1995;56:PL45-PL50. (Pubitemid 24380184)
3. Elkader AK, Brands B, Dunn E, et al. Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. J Clin Psychopharmacol. 2009;29:77-81.
4. Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81:719-728. (Pubitemid 46625109)
5. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004;16:36-44. (Pubitemid 37532283)
6. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro. Drug Metab Dispos. 2003;31:742-747.
7. Crettol S, Deglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005;78:593-604. (Pubitemid 41773635)
8. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab. 2008;9:598-610.
9. Roy P, Yu LJ, Crespi CL, et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999;27:655-666. (Pubitemid 29252439)
10. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287-300. (Pubitemid 36734384)
11. Totah RA, Sheffels P, Roberts T, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008;108:363-374. (Pubitemid 351304229)
12. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496-526. (Pubitemid 350116943)
13. Zanger UM, Klein K, Saussele T, et al. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8:743-759. (Pubitemid 47288975)
14. Zanger UM, Turpeinen M, Klein K, et al. Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392:1093-1108.
15. Wang SC, Ho IK, Wu SL, et al. Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients. Biomed Chromatogr. 2010;24:782-788.
16. Marsden J, Farrell M, Bradbury C, et al. Development of the treatment outcomes profile. Addiction. 2008;103:1450-1460.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
18. Wang SC, Ho IK, Wu SL, et al. Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients. Biomed Chromatogr. 2010;24:782-788.
19. Yuan HY, Chiou JJ, Tseng WH, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006;34:W635-641.
20. Rodi CP, Darnhofer-Patel B, Stanssens P, et al. A strategy for the rapid discovery of disease markers using the MassARRAY system. Biotechniques. 2002;(suppl):62-66, 68-69.
21. Tost J, Gut IG. Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin Biochem. 2005;38:335-350. (Pubitemid 40342864)
22. Barrett J, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265. (Pubitemid 40202029)
23. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73:1162-1169. (Pubitemid 37414228)
24. US Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://fda-drugs. legalview.info/legal-issue/8-mop/fda-alerts/drug-interactions-table-of- substrates-inhibitors-and-inducers/446719/. Accessed April 14, 2011.
25. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at: http://medicine.iupui.edu/ clinpharm/ddis/. Accessed April 14, 2011.
26. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265. (Pubitemid 40202029)
27. Stocker H, Kruse G, Kreckel P, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:4148-4153. (Pubitemid 39434868)
28. Busby WF Jr, Ackermann JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos. 1999;27:246-249. (Pubitemid 29072079)
29. Miksys S, Lerman C, Shields PG, et al. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003;45:122-132. (Pubitemid 36700458)
30. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol. 1999;47:403-412. (Pubitemid 29161273)
31. Shinderman M, Maxwell S, Brawand-Amey M, et al. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend. 2003;69:205-211. (Pubitemid 36259782)
32. Kharasch ED, Hoffer C, Whittington D, et al. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology. 2009;110: 660-672.
33. Esteban J, Pellin Mde L, Gimeno C, et al. Increase of R-/S-methadone enantiomer concentration ratio in serum of patients treated with either nevirapine or efavirenz. Drug Metab Lett. 2008;2:269-274.
34. Cao YJ, Smith PF, Wire MB, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy. 2008;28:863-874. (Pubitemid 351875165)
35. Novick DM, Kreek MJ, Arns PA, et al. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. Alcohol Clin Exp Res. 1985;9:349-354. (Pubitemid 16247129)